Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cristina Libenciuc

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Bulletin Du Cancer|August 7, 2016
[Not Available]Christine Mateus, Cristina Libenciuc, Caroline Robert
Cell Reports|November 25, 2020
Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid OxidationShensi Shen, Sara Faouzi, Sylvie Souquere, et al.
Nature Reviews. Clinical Oncology|May 5, 2016
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combinationCeline Boutros, Ahmad Tarhini, Emilie Routier, et al.
Nature Medicine|October 31, 2018
Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanomaMichaël Cerezo, Ramdane Guemiri, Sabine Druillennec, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Bulletin Du Cancer|August 7, 2016
[Not Available]Christine Mateus, Cristina Libenciuc, Caroline Robert
Cell Reports|November 25, 2020
Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid OxidationShensi Shen, Sara Faouzi, Sylvie Souquere, et al.
Nature Reviews. Clinical Oncology|May 5, 2016
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combinationCeline Boutros, Ahmad Tarhini, Emilie Routier, et al.
Nature Medicine|October 31, 2018
Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanomaMichaël Cerezo, Ramdane Guemiri, Sabine Druillennec, et al.
Pageof 1